A Dose Ranging Study Evaluating Efficacy and Safety of NI-03

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 03

Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis Study 02

Three-year Follow-up Study of Subjects Who Participated in a Previous Lambda (BMS-914143) Chronic Hepatitis C Clinical Trial

Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease

A Safety and Efficacy Study of Relamorelin in Diabetic Gastroparesis Study 04

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

The Diabetic and Idiopathic Gastroparesis Efficacy, Safety, and Tolerability (DIGEST) Study

Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis

Randomized Global Phase 3 Study to Evaluate the Impact on NASH With Fibrosis of Obeticholic Acid Treatment

Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)

Filgotinib in Long-Term Extension Study of Adults With Crohn's Disease

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis